Effect of Androgen-Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients.
Serhan ÜnlüJunghee Jenny ShinJennefer Par-YoungMichael SimonovJoseph VinetzDaniel P PetrylakInsoo KangJoseph W KimPublished in: Cancer investigation (2022)
TMPRSS2 is utilized by SARS-CoV-2 for cellular entry. Androgen-Androgen receptor directed therapy (A/ARDT) downregulates expression of TMPRSS2. We hypothesized A/ARDT might protect prostate cancer (PCa) patients from poor COVID-19 outcome. A retrospective analysis of PCa patients with COVID-19 infection was performed. 146 PCa cases were identified, 17% were on A/ARDT. Hospitalization rates were same 52% (OR = 0.99, 0.41-2.24). Mean hospitalization was 9.2 (Range: 1-25) and 14.9 (Range: 2-47) days in A/ARDT and non-A/ARDT groups, respectively. While definitive conclusions cannot be made regarding outcome differences between groups due to lack of statistical significance, these data generate hypothesis that A/ARDT might shorten hospitalization stay.
Keyphrases
- sars cov
- prostate cancer
- end stage renal disease
- coronavirus disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- poor prognosis
- stem cells
- respiratory syndrome coronavirus
- long non coding rna
- deep learning
- electronic health record
- cell therapy
- smoking cessation
- data analysis